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Abstract Three cell surface molecules participate in lnterleu- 
kin-1 (IL-1) binding and signal generation, the two distinct types 
of receptors (type ! IL-IR and type II IL-IR) and the IL-1 
receptor accessory protein 0L-1RAcP). Low surface expression 
hampers the detection of all three components on a protein level 
in most cell types, thus the highly sensitive RT-PCR was used to 
analyse the mRNA expression in a panel of 18 murine cell types 
of different hemopoietic lineages and fibroblasts. The transcrip- 
tion of both types of IL-1 receptors was detected in all cell lines 
tested. In most cell lines the IL-IRAcP was co-expressed with the 
IL-I receptors, and only these lines responded to IL-I. However, 
in three cell lines no mRNA for the IL-IRAcP could be detected, 
and these cells did not respond to [L-I. These results suggest hat 
the expression of the IL-IRAcP correlates with IL-I respon- 
siveness and they point to a pivotal role for the IL-IRAcP in IL-I 
signal generation. 
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1. Introduction 
Interleukin-1 (IL-1) is an important pro-inflammatory c to- 
kine with local and systemic effects resulting in a multitude of 
biological responses by a wide variety of target cells [I]. As a 
polypeptide mediator IL-1 exerts its function by binding to 
specific plasma membrane receptors.Two distinct forms of 
receptors for IL-1 have been cloned in mammalian cells, the 
type I IL-1R with a molecular mass of 80 kDa [2] and the type 
II IL-1R with a molecular mass of 68 kDa [3]. Whereas the 
type I IL-1R binds IL-1 and generates a signal in the target 
cell, the type II IL-1R binds the ligand but does not lead to an 
intracellular esponse. Its function has been discussed as a 
ligand sink to distract IL-1 from the type I IL- IR,  thus serv- 
ing rather as a decoy receptor [4,5]. The type II IL-1R can 
exert this function in a plasma membrane anchored form and 
in a soluble form [6]. 
A cell type specific expression of these two types of IL-1 
receptors was reported. T-cells and fibroblasts express mainly 
type I IL-1R, whereas B-cells and monomyeloic ells bear 
predominantly type II IL-1R. Older reports state that some 
cell lines express one type of receptor exclusively, whereas 
recent data suggest that a co-expression of both types of 
IL-1 receptors is possible [7]. Very recently, an IL-1 receptor 
accessory protein (IL-RAcP) has been identified and cloned 
[8]. This molecule does not bind IL-1 itself but seems to en- 
hance the affinity of the type I IL-1R for its ligand, suggesting 
that the IL-1R is a multi-subunit complex. 
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We addressed the question whether IL-1 receptors are co- 
expressed and whether the expression of  the IL-1RAcP corre- 
lates with the responsivess of cells to IL-1. In all 18 murine 
cell lines tested a coexpression of mRNA of both types of 
receptors was detected by RT-PCR, and most, but not all 
cell lines expressed mRNA for the IL-1RAcP. Interestingly, 
the cell lines lacking mRNA for the IL-1RAcP were found to 
be unresponsive to IL-1, as ascertained by the two most com- 
mon early IL-1 effects known from literature: NFkB activa- 
tion and activation of the IL-1 receptor associated protein 
kinase IRAK [9,10], demonstrating a strong correlation of 
IL-1 responsiveness and expression of IL-1RAcP. 
2. Materials and methods 
2.1. Reverse transcriptase polymerase chain reaction (RT-PCR) 
2.1.1. Reverse transcriptase r action. RNA from 10 7 cells was ex- 
tracted using RNA-Zol (AGS, Heidelberg). The isolated RNA was 
treated with DNase 1 (Boehringer Mannheim) using standard condi- 
tions. The RNA was extracted by a phenol/chloroform/isoamyl alco- 
hol treatment [11]. Reverse transcription was carried out in a final 
volume of 10 p-1 per sample. For each reaction 1 p-1 reverse-transcrip- 
tion buffer (Stratagene), 1 p-1 DTT solution (100 mM, Stratagene), 
5.5 p-I DEPC water, 1 p-1 dNTPs (10 mM of dATP, dCTP, dGTP, 
dTTP each, New England Biolabs), 0.5 ~tl random hexamers (100 p-M, 
Pharmacia), 0.5 Ixl reverse transcriptase (50 U/p.l, Stratagene) and 0.5 
btl template RNA (1 p-g/p-l) were mixed on ice, overlaid with mineral 
oil (Sigma) and incubated in a thermocycler (Vario V, Landgraf, 
Hannover) with a program of 60 min at 37°C, 5 min at 99°C and 5 
min at 5°C. As negative control the reverse transcriptase was substi- 
tuted with DEPC-water. 
2.1.2. Polymerase chain reaction. The cDNA was amplified with 
three different pairs of primers. IL-1RI (product length: 363 bp), 
primer 1: CTG GAG ATT GAC GTA TGT ACA GAA TAT 
CCA AAT; primer 2: ATC CCC GGC AAT GTG GAG CCG 
CTG TGG GAA GGT GGC CTG TGT. IL-1RII (product length: 
414 bp), primer 1: TTC ACC ACT CCA ACA GTG GTG CAC 
ACA GGA; primer 2: CAA GTA GGA GAC ATG AGG CAG 
AGA TGC TTC AGT. IL-1RAcP (product length: 677 bp), primer 
1 : AAC CAT CGG TCA CTT GGT ATA AGG G; primer 2: TTC 
ATC TGT TCC AAA GTG AGC TCG G. The reactions were per- 
formed in a final volume of 50 p-l. 10 Ixl cDNA solution were added to 
a mixture of 1.6 p-1 magnesium chloride (50 mM, GibcoBRL), 4 p-I 
PCR buffer (GibcoBRL), 0.8 p-I dNTPs, 25.4 p-1 DEPC water, 0.2 p-I 
Taq polymerase (GibcoBRL) and 4 p-I of each primer 1 and primer 2 
(10 Ismol/1). The samples were overlaid with mineral oil (Sigma) and 
placed in a Vario V thermocyler (Landgraf). Program: 5 min at 95°C, 
40 cycles with 1 min at 95°C, 1 rain annealing (65°C for IL-1RI and 
IL-1RAcP, 55°C for IL-1RII), 1 min at 72°C followed by 7 min at 
720C. The PCR products were analysed on a 1.5% agarose gel and 
detected via ethidium bromide staining [11]. Specificity of the resulting 
PCR products was ascertained by performing a restriction digest with 
tlinfI (20 000 U/ml, AGS, Heidelberg). 
2.2. Measurement of 1L-1 responses 
IRAK activation was measured in type I IL-1R immunoprecipitates 
in an in vitro kinase assay as described recently [9]. D10N prolifera- 
tion assays were performed as described [12]. For determination of 
PGE2 cells were grown to confluency and incubated with or without 
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10 ng/ml IL-11] for 24 h. The supernatants were centrifuged (8 min, 
1200 rpm) and analysed by ELISA as described earlier [13]. Interleu- 
kin-2 (IL-2) was measured in a bioassay using the IL-2 dependent 
murine cytotoxic T cell line CTLL [14]. 
2.3. Electrophoretic mobility shift assays (EMSA) 
Nuclear extracts from 2 × 107 cells were obtained using a standard 
protocol (e.g. [15]), including aNonidet P-40 solubilization step. Bind- 
ing reactions were carried out with 5 p.g protein. An oligonucleotide 
containing the NF~cB binding sequence (TGA CAG AGG GGA CTT 
TCC AGA GA [15]) was radiolabeled with the T4 polynucleotide 
kinase (Pharmacia, Freiburg). For the binding reaction 5 ~tg nuclear 
extract (1)11) was preincubated with (for supershift) or without 1 ~tl 
c-tel antibody (0.1 ~tg/Ixl, Santa Cruz) and 4.5 or 5.5 lal H20 for 30 
min at room temperature. This mixture was incubated with 1 ~tl of the 
radiolabelled double-stranded oligonucleotide (~0.1 pmol with 
12000 cpm), 1 ktl competitor DNA (1 Ixg/Ixl poly(dldC)) and 1 ~tl 
HP buffer (10 mmol/1 Tris, 10 mmol/1 EDTA, 10 mmol/l DTT, 500 
mmol/1 NaCI, 50% glycerol, pH 7.5) for 30 min at room temperature. 
The binding reaction was stopped by adding 2 txl stop buffer (0.5% 
bromophenol b ue, 50% glycerol). The protein/DNA complexes were 
separated in a polyacrylamide gel (4%). 
3. Results 
3.1. Co-expression of mRNA of type I and type H IL-1 
receptors 
A panel of 18 murine cell lines of different hemopoietic 
lineages and fibroblasts was analysed for gene expression of 
the two types of IL-1 receptors in a qualitative manner. The 
selected primers for the type I IL-1R led to the amplification 
of a 363 bp product (Fig. 1). The primers designed for the 
type II IL-1R resulted in a 414 bp product (Fig. 2). Both 
products were detected in all cell lines tested (summarized in 
Table 1). HinfI digestion of these PCR products resulted in 
the fragments expected from the sequence data, confirming 
the specificity of the two products (data not shown). Contam- 
ination of the RNA preparations with genomic DNA was 
excluded by performing a DNAse digestion step and by in- 
cluding negative controls in the absence of reverse transcrip- 
tase. In these negative controls no signals were detected. 
3.2. IL-1RAcP is not expressed in all IL-1 R positive cell lines 
In most of the cell lines expressing IL-1 receptors a signal of 
617 bp could be detected for the mRNA of the IL-1RAcP 
(Fig. 3). Restriction digests of this PCR product yielded the 
expected fragments, again demonstrating the specificity of the 
signal obtained in the RT-PCR (data not shown). However, in 
the monomyeloic ell line FDCP1, and in the thymomas $49 
WT and $49 Cyc-  no signal was detected (Fig. 3 and sum- 
marized in Table 1). Inclusion of aldolase-specific primers as 
positive controls (aldolase) resulted in a strong signal of 464 
bp in all reactions performed (data not shown), proving that 
false negative results due to degradation of RNA can be ex- 
cluded. 
3.3. Correlation of IL-1RAcP expression and IL-1 
responsiveness 
In order to check the biological implications of the lack of 
IL-1RAcP expression, the IL-1 reactivity of those cells which 
do not express the IL-1RAcP was tested. In contrast o con- 
trol cells (EL-4 6.1, D10N, L929, Swiss 3T3), an IL-1 induced 
activation of IRAK could not be detected in the cell lines 
FDCP1 and $49 (data not shown). However, as IRAK acti- 
vation is measured in immunoprecipitates of type I IL-1R this 
assay may be too insensitive in cells expressing very low num- 
bers of receptors. Thus, an EMSA with an oligonucleotide 
probe specific for NF~B was performed as a more sensitive 
technique. In nuclear extracts of EL4 6.1 cells a very strong 
IL-1 induced activation of a NF~B-like binding activity was 
easily observed. A supershift experiment with an anti-c-rel 
antibody, a component of the NFkB complex, shows the con- 
Table 1 
Summary of the RT-PCR analysis of the IL-1 receptor components 
Cell line Cell type Source of cells a IL-1 RI IL-1 RII IL-1 RI AcP 
Transcript b Number c Transcript b Number c Transcript b Numbeff 
70Z/3 pre B-cell ATCC + 3 + 3 + 2 
SPGM1 2D8 pre B-cell WEHI + 4 + 3 + 2 
SPGM1 x bcl pre B-cell, bcl trans- WEHI + 2 + 2 + 2 
fected 
Wehi 231 B-cell WEHI + 6 + 3 + 2 
FDCP1 promonocyte WEHI + 3 + 2 - 4 
2D8D macrophage ATCC + 2 + 3 + 2 
H 4-7 macrophage ATCC + 2 + 3 + 2 
P388 D1 macrophage ATCC + 3 + 2 + 2 
PU 5-1.8 macrophage ATCC + 2 + 1 + 2 
RAW 264 macrophage ATCC + 3 + 2 + 2 
Wehi 3B macrophage WEHI + 2 + 3 + 2 
BW 5147 T-cell lymphoma ATCC + 6 + 2 + 2 
D10N T-helper cell (TH2) SH + 20 + 51 + 5 
EL-4 6.1 T-cell lymphoma RMcD + 11 + 3 + 12 
$49 WT T-cell lymphoma ATCC + 3 + 1 - 4 
S 49 Cyc- T-cell lymphoma, GS + 2 + 2 - 2 
adenylate cyclase 
deficient 
L929 fibroblast DSM + 4 + 2 + 2 
Swiss 3T3 fibroblast DSM + 3 + 2 + 2 
~Source of cell line - ATTC: American Type Culture Collection, Rockville, Maryland, USA; WEHI: The Walter and Eliza Hall Institute of 
Medical Research, Melbourne, Australia; SH: kind gift of S. Hopkins, Manchester, UK; RMcD: kind gift of R. McDonald, Lausanne, Switzer- 
land; GS: kind gift of G. Schultz, Berlin, Germany; DSM: Deutsche Sammlung yon Mikroorganismen u d Zellkulturen, Braunschweig, Germany. 
bSignal intensity: --, no signal; +, signal. 
CNttmber of positive or negative proofs. 
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tribution of this molecule in the IL-1 induced DNA binding 
activity (Fig. 4). Neither FDCP1 nor $49 WT showed any 
IL-1 induced NFkB binding capacity. A weak basal binding 
activity in nuclear extracts of these cell lines was not influ- 
enced by IL-1 treatment and is probably due to signalling 
pathways activated by growth factors necessary for the pro- 
liferation of these cell lines (e.g. IL-3). In parallel, assays were 
performed with cell lines expressing IL-1RAcP mRNA, which 
proved to be IL-1 responders. We observed IL-1 induced IL-2 
production in EL-4 6.1, IL-1 dependent proliferation of 
D10N, and IL-1 induced PGE2 production of Swiss 3T3 
(summarized in Table 2). 
4. Discussion 
Presently, it is unclear which molecules of the IL-1 receptor 
complex actually define the IL-1 responsiveness of cells. On 
the plasma membrane three molecules are involved in IL-1 
binding, the two types of receptors and the IL-1R accessory 
protein. The type I IL-1 R binds IL-1 and initiates signal 
transduction, whereas the type II IL-1R only binds and sup- 
posedly distracts IL-1 from the type I IL-1R [16,17], thereby 
elevating the threshold of IL-1 concentration necessary to 
elicit effects. This is suggested by experiments in cell lines 
possessing a given number of type I IL-1R in which over- 
expression of type II IL-1R results in a shift of IL-1 dose- 
response curves to higher concentrations [18]. However, not 
only may this distraction of ligand by type II IL-1R play a 
role in defining the sensitivity of cells to IL-1, but also the 
presence and level of expression of the IL-1RAcP, as sug- 
gested by the results described here. 
Thus, the aim of this study was two-fold. We wanted to 
clarify whether co-expression of the two types of IL-1 recep- 
tors is common and whether a correlation can be found be- 
tween IL-1 response of cells and expression of the IL-1RAcP. 
Firstly, the screening of murine cell lines of different hemo- 
poietic lineages and fibroblasts hows that the mRNAs for 
both types of IL-1 receptors are widely co-expressed. In 
fact, we could not find any cell lines which synthesized either 
one species of mRNA for IL-1 receptors or none at all. Qua- 
litative RT-PCR does not allow for quantitation of the 
achieved results, so neither a statement on the ratio of 
mRNA species which is expressed in a given type of cell can 
be made, nor can anything be stated concerning levels of 
protein expression. However, as mRNA expression is a pre- 
requisite for protein synthesis, the assumption can be made 
that functional protein is expressed. As most cell lines and 
especially normal tissue cells express extremely low numbers 
of IL-1 receptors on their surface, detection and distinction of 
the two types of receptors is practically often unfeasible. In 
some cells in which both mRNAs are present, both types of 
IL-1 receptors can be visualized by crosslinking iodinated 
IL-I~, such as in D10N cells, in others only type I IL-1R 
can be demonstrated (e.g. EL 4) [7], and in still others such 
as 70Z/3 only type II IL-1R can be shown by this technique, 
yet 70Z/3 can respond to IL-1 [15,19], thus indicating that 
Table 2 
Correlation of IL-1RAcP expression and IL-1 responsiveness 
Cell line IL-1RAcP expression IL-1 mediated signalling effects 
IRAK activation NFlcB shift 
Other IL-1 mediated effects 
D10N + + + 
EL-4 6.1 + + + 
FDCP 1 -- - -- 
L929 + + not tested 
$49 WT - - - 
Swiss 3T3 + + not tested 
proliferation 
IL-2 production 
not tested 
not tested 
not tested 
PGE2 production 
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functional type I IL-1R must be present. Therefore, RT-PCR 
seemed to be the only technique to measure IL-1 receptor 
expression with a sensitivity high enough to achieve results 
at all. 
Secondly, cells lacking IL-1RAcP seem to be unable to 
respond to IL-1. 
IL-1 responsiveness can be measured at different levels. One 
of the first events measurable after IL-1 binding to the type I 
IL-1R is the activation of IRAK, the IL-1R associated serine/ 
threonine protein kinase [9,10]. Further downstream in the 
IL-1 induced signalling cascade NFkB activation and translo- 
cation to the nucleus is a common event observed in many cell 
types (reviewed in [20]). In addition, biological effects such as 
IL-1 dependent proliferation of D10N cells, IL-1 induced IL-2 
synthesis in EL-4 cells or prostaglandin production in fibro- 
blasts can be measured. As no information was available on 
IL-1 induced effects for the cell lines $49 and FDCP1, which 
are negative for IL-1RAcP, we tried to measure IRAK activa- 
tion by an in vitro kinase assay with type I IL-1R immuno- 
precipitates and NFkB activation by performing EMSAs, re- 
spectively. No effect of IL-1 could be observed in these cell 
lines, whereas IL-1 induced the expected effects in control 
cells, which expressed IL-1RAcP mRNA. This suggests that 
IL-1RAcP has to be expressed to facilitate signal transduction 
by the type I IL-1R. The fact that an antibody raised against 
the IL-1RAcP may abrogate an IL-1 response as described 
[21] strongly supports the notion that IL-1 RAcP is an essen- 
tial co-receptor molecule in the signal generating complex of 
the type I IL-1 receptor. 
Acknowledgements: We thank Dr. Diana Boraschi, L'Aquila, Italy, 
for support, Dr. Werner Falk, Regensburg, Germany, for many help- 
ful discussions, and Prof. L. Floh6 and Dr. J. Paulsen (Gesellschaft 
f~ir Biotechnologische Forschung, Braunschweig,Germany) for syn- 
thesis of specific primers and for Interleukin-2 for the cell culture. 
. r  
.c: 
"r" 
1< 
:~ r,. 
1198 bp 
517 bp 
396 bp 
IL-1RAcP 
(677 bp) 
1198 bp 
517 bp 
396 bp 
IL-1 RAcP 
(677 bp) 
Fig. 3. Agarose gel electrophoresis with the IL-1RAcP RT-PCR products. 
108 
FDCP1 [ S49WT [ EL-46.1 
I + " + [ - I + I L - lbeta  
+ - + , -  + -+ - + - + c-relantibody 
A 
B 
B 
Fig. 4. IL-1 does not induce NF~cB activation in IL-1RAcP deficient 
cell lines. The two IL-1RAcP deficient cell lines (FDCP1 and $49 
WT) and the IL-1 responder EL-4 6.1 were incubated without IL-1 
(-IL-1) or with 10 ng/ml of rhlL-11~ (+IL-1). Nuclear proteins were 
prepared, incubated with a radiolabeled double-stranded cDNA con- 
taining the NFkB binding motif, and an EMSA was performed. IL- 
l induced a strong shift in EL-4 6.1, resulting in two bands (bands 
B), which was not observed in FDCP1 or in $49 WT. Supershift ex- 
periments using an anti-crel antibody identified the complex and 
demonstrated the participation of crel as a component of the 
NF~B-like binding activity (band A). 
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